CBDCA or CDDP/PEM/Bev as Induction Regimen Prior to Surgery in Patients With Non-SQ NSCLC Stage II and III
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Modified NAVAL study
- 12 Jul 2018 Status changed from recruiting to completed.
- 01 Jul 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 17 Aug 2013 New trial record